Effect of Melatonin on Sleep Patterns of Resident Trainees During Night Float Shift

Sponsor
University of Virginia (Other)
Overall Status
Recruiting
CT.gov ID
NCT05701969
Collaborator
(none)
50
1
2
25
2

Study Details

Study Description

Brief Summary

Anesthesiology residency requires extended and overnight shifts, which may negatively impact the quantity and quality of sleep.

Previous studies have investigated the effect of night float shift work on anesthesiology resident sleep and performance and demonstrated that total sleep quantity and time spent in deep and REM sleep were significantly reduced during night float and did not return to baseline after 3 nights of recovery.

Melatonin is a hormone produced by the pineal gland, which regulates the circadian rhythm that governs sleep. Exogenous melatonin may be used as a sleep aid and is available over the counter in the United States. Melatonin is effective in realigning the circadian rhythm disorder caused by night shift work and increasing sleep duration; however, melatonin's effect on improving sleep in resident trainees has not been investigated. The investigators propose a prospective double-blinded randomized control trial to investigate the effect of melatonin on sleep quantity and quality in resident physicians assigned to a night float system.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Melatonin
  • Other: Placebo
Early Phase 1

Detailed Description

Residents in Post-Graduate Years 1-7 enrolled in residency programs with a night float system (anesthesiology, general surgery, obstetrics and gynecology, general medicine, and pediatrics) will be invited to participate in the study. A clinical study coordinator will assist in obtaining informed consent. After informed consent is obtained, participants will be randomized to receive either 3 mg melatonin or a matching placebo control. Medications will be prepared and randomization performed by the UVA Pharmacy. Both participants and study coordinators will be blinded to the treatment group. Participants will be provided with a 12-day supply of medication at the start of the night float week. They will be instructed to take one capsule at least 20 minutes prior to going to bed at night or during the day after completing their night float shift. Subjects will be given a portable EEG monitor (ZMachine© Insight+ monitor (General Sleep Corporation, Euclid, OH))12 and will be shown how to apply the machine, monitor its functionality, and troubleshoot minor issues. They will be asked to wear the device for 2-3 nights of baseline sleep, 5-6 days of sleep during night float, and 3-4 nights of recovery following night float, for a total of 12 consecutive days. Baseline sleep data will serve as a control for each subject. EEG data collected will include: Light Sleep, Deep Sleep, REM, Arousals, Total Sleep Time, Sleep Efficiency, Latency to Persistent Sleep, Wake After Sleep Onset, Total Deep Sleep, Total REM Sleep, and Time Out of Bed. Data from two different night float periods separated by at least 2 weeks will be collected (one-week melatonin and one-week placebo in random order). Residents will also be asked to complete a daily questionnaire assessing daytime sleepiness (Epworth Sleepiness Scale) and the use of caffeine or other stimulants.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
a prospective double-blinded randomized control trial to investigate the effect of melatonin on sleep quantity and quality in resident physicians assigned to a night float system.a prospective double-blinded randomized control trial to investigate the effect of melatonin on sleep quantity and quality in resident physicians assigned to a night float system.
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
The research pharmacy will randomize the study.
Primary Purpose:
Treatment
Official Title:
Effect of Melatonin on Sleep Patterns of Resident Trainees During Night Float Shift
Actual Study Start Date :
May 30, 2022
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Melatonin group

These subjects will receive melatonin

Dietary Supplement: Melatonin
Melatonin

Placebo Comparator: Placebo group

These subjects will receive placebo

Other: Placebo
Placebo control

Outcome Measures

Primary Outcome Measures

  1. Total Sleep Time (TST) [2 weeks]

Secondary Outcome Measures

  1. Light Sleep [2 weeks]

  2. Deep Sleep [2 weeks]

  3. Rapid Eye Movement Sleep [2 weeks]

  4. Latency to Persistent Sleep (LPS) [2 weeks]

  5. Wake after Sleep Onset (WASO) [2 weeks]

  6. Sleep Efficiency (SE) [2 weeks]

Other Outcome Measures

  1. Epworth Sleepiness Scale [2 weeks]

    Score 0-24

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Post-Graduate Year 1-5

  • Current enrollment in anesthesiology, general surgery, obstetrics and gynecology, general medicine, or pediatrics residency at the Unversity of Virginia

Exclusion Criteria:
  • Current use of sleep aids

  • Diagnosed sleep disorder

  • History of a pacemaker or other medical device.

  • pregnant or breast-feeding females

  • Bleeding disorders

  • Depression

  • High blood pressure

  • Seizure disorders

  • History of transplant on immunosuppression therapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Virginia Charlottesville Virginia United States 22908-0710

Sponsors and Collaborators

  • University of Virginia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lauren Dunn, MD, Assistant Professor, University of Virginia
ClinicalTrials.gov Identifier:
NCT05701969
Other Study ID Numbers:
  • HSR210118
First Posted:
Jan 27, 2023
Last Update Posted:
Jan 27, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 27, 2023